Abstract
Objective: assess the lipid-altering efficacy and safety of ezetimibe/simvastatin single tablet product compared with rosuvastatin at the approved usual starting, next highest, and maximum doses. Research design and methods: Double-blind, multicenter, 6-week, parallel-group study in hypercholesterolemic patients (n = 2959). Patients were randomized based on stratification by low-density lipoprotein cholesterol (LDL-C) levels to ezetimibe/simvastatin or rosuvastatin, respectively, at the usual starting (10/20 or 10 mg/day), the next highest (10/40 or 20 mg/day), and maximum doses (10/80 or 40 mg/day). Results: At all doses and across doses, ezetimibe/simvastatin reduced LDL-C levels significantly more (52-61%) than rosuvastatin (46-57%; p ≤, 0.001). Significantly greater percentages of all patients (p <0.001) and high risk patients (p ≤, 0.005) attained LDL-C levels <70 mg/dL (1.8 mmol/L) following ezetimibe/simvastatin treatment compared with rosuvastatin at the prespecified doses and across doses. Ezetimibe/simvastatin also produced significantly greater reductions in total cholesterol (p <0.001), non-high-density lipoprotein cholesterol (p <0.001), lipid ratios (p
| Original language | English |
|---|---|
| Pages (from-to) | 2041-2053 |
| Number of pages | 13 |
| Journal | Current Medical Research and Opinion |
| Volume | 22 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 2006 |
Fingerprint
Keywords
- Apolipoprotein B
- CRP
- Ezetimibe/simvastatin
- HDL-C
- Hypercholesterolemia
- Lipids
- Rosuvastatin
- Statins
ASJC Scopus subject areas
- Medicine(all)
Cite this
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. / Catapano, Alberico L.; Davidson, Michael H.; Ballantyne, Christie M.; Brady, William E.; Gazzara, Russell A.; Tomassini, Joanne E.; Tershakovec, Andrew M.
In: Current Medical Research and Opinion, Vol. 22, No. 10, 10.2006, p. 2041-2053.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients
AU - Catapano, Alberico L.
AU - Davidson, Michael H.
AU - Ballantyne, Christie M.
AU - Brady, William E.
AU - Gazzara, Russell A.
AU - Tomassini, Joanne E.
AU - Tershakovec, Andrew M.
PY - 2006/10
Y1 - 2006/10
N2 - Objective: assess the lipid-altering efficacy and safety of ezetimibe/simvastatin single tablet product compared with rosuvastatin at the approved usual starting, next highest, and maximum doses. Research design and methods: Double-blind, multicenter, 6-week, parallel-group study in hypercholesterolemic patients (n = 2959). Patients were randomized based on stratification by low-density lipoprotein cholesterol (LDL-C) levels to ezetimibe/simvastatin or rosuvastatin, respectively, at the usual starting (10/20 or 10 mg/day), the next highest (10/40 or 20 mg/day), and maximum doses (10/80 or 40 mg/day). Results: At all doses and across doses, ezetimibe/simvastatin reduced LDL-C levels significantly more (52-61%) than rosuvastatin (46-57%; p ≤, 0.001). Significantly greater percentages of all patients (p <0.001) and high risk patients (p ≤, 0.005) attained LDL-C levels <70 mg/dL (1.8 mmol/L) following ezetimibe/simvastatin treatment compared with rosuvastatin at the prespecified doses and across doses. Ezetimibe/simvastatin also produced significantly greater reductions in total cholesterol (p <0.001), non-high-density lipoprotein cholesterol (p <0.001), lipid ratios (p
AB - Objective: assess the lipid-altering efficacy and safety of ezetimibe/simvastatin single tablet product compared with rosuvastatin at the approved usual starting, next highest, and maximum doses. Research design and methods: Double-blind, multicenter, 6-week, parallel-group study in hypercholesterolemic patients (n = 2959). Patients were randomized based on stratification by low-density lipoprotein cholesterol (LDL-C) levels to ezetimibe/simvastatin or rosuvastatin, respectively, at the usual starting (10/20 or 10 mg/day), the next highest (10/40 or 20 mg/day), and maximum doses (10/80 or 40 mg/day). Results: At all doses and across doses, ezetimibe/simvastatin reduced LDL-C levels significantly more (52-61%) than rosuvastatin (46-57%; p ≤, 0.001). Significantly greater percentages of all patients (p <0.001) and high risk patients (p ≤, 0.005) attained LDL-C levels <70 mg/dL (1.8 mmol/L) following ezetimibe/simvastatin treatment compared with rosuvastatin at the prespecified doses and across doses. Ezetimibe/simvastatin also produced significantly greater reductions in total cholesterol (p <0.001), non-high-density lipoprotein cholesterol (p <0.001), lipid ratios (p
KW - Apolipoprotein B
KW - CRP
KW - Ezetimibe/simvastatin
KW - HDL-C
KW - Hypercholesterolemia
KW - Lipids
KW - Rosuvastatin
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=33750531657&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750531657&partnerID=8YFLogxK
U2 - 10.1185/030079906X132721
DO - 10.1185/030079906X132721
M3 - Article
C2 - 17022864
AN - SCOPUS:33750531657
VL - 22
SP - 2041
EP - 2053
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
SN - 0300-7995
IS - 10
ER -